MYGN - Myriad Genetics Inc.

MYGN valuation $2.73 billion

Stock Price

37.42
Change: ↓ -0.92 (-2.3996%)
Last Update: 2015-01-30T16:16:37-05:00
Shares Outstanding: 72,985,326
Industry: Medical Diagnostics & Research

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease.

Stock Price Data

Open: 38.27 Previous Close: 38.34
High: 38.61 Low: 37.36
Bid: 37.39 Ask: 37.51

Bid Size: 100 Ask Size: 900
Raw Bid Size: 1 Raw Ask Size: 9
Trade Volume: 7272 Share Volume: 1032061
Last Trade Date: 2015-01-30 Last Trade Time: 16:15:00-05:00
Vwap: 37.611791 EPS: 1.78

Fundamental Data

PE ratio: 21.50 PB ratio: 3.834
Beta: 0.884857

52 Week High: 42.50 52 Week Low: 26.09
52 Week High Vwap: 44.8108 52 Week Low Vwap: 27.2418
52 Week High Volume: 9315730 52 Week Low Volume: 131465
52 Week Avg Volume: 1243099
* Quotes delayed 15 minutes

Related Stocks

StockCompany namePrice
GENE Genetic Technologies Ltd Sponsored ADR 2.79
PKI PerkinElmer Inc. 45.67
A Agilent Technologies Inc. 37.77
BGMD BG Medicine Inc. 1.06
TMO Thermo Fisher Scientific 125.29
APPY Venaxis Inc. 0.51
DGX Quest Diagnostics Inc. 71.15
CPHD CEPHEID 56.51
QGEN Qiagen N.V. 22.93
LH Laboratory Corp. of America Holdings 114.78